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Abstract
Background: Women with untreated phenylketonuria (PKU) are at an increased
risk to have offspring with multiple abnormalities due to teratogenic effects of
hyperphenylalaninaemia. Treatment goals include blood phenylalanine concentrations
between 120 and 360 µmol/L, however, there are limited pieces of evidence for
the practical management of pregnant PKU patient and prediction of phenylalanine
tolerance changes during a course of pregnancy.
Case: We report the case of a mother with classical PKU (p.R408W/p.R408W) and the
course of her two pregnancies with low phenylalanine tolerance increase (347mg and
227mg) despite the rewarding collaboration with a nutritionist.
Conclusion: This case report does not confirm the observation that a very low
phenylalanine tolerance increase in pregnancy of PKU patient is a marker of coexisting
PKU-affection in fetus.
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1. Introduction
Classical phenylketonuria (PKU, OMIM 261600),
caused by a deficiency of the biopterin-dependent
cytosolic enzyme phenylalanine hydroxylase (PAH,
EC 1.14.16.1), is the relatively frequent inborn error of
metabolism. Over the last half century, population
newborn screening has made PKU one of the
most spectacular examples of diseases whose
manifestations can be prophylactically managed
via early intervention (1-3). In PKU, the essential
aromatic amino acid phenylalanine (with the for-
mula C9H11NO2, Phe), cannot be converted to
4-hydroxyphenylalanine (tyrosine) and therefore
pathologically accumulates. Dietary intervention
restricting Phe intake has converted PKU to a
disease with essentially normal neurodevelopment
and social integration (1-3). Phe tolerance (mg/day)
is the amount of this amino acid in food that those
with PKU can eat and maintain acceptable blood
Phe levels. Clinical determination of Phe tolerance
relies on the systematic assessment of blood Phe
levels in relations to Phe intake from detailed
menus provided by the patient. A protein substitute
free of Phe, but nutritionally complete in all other
amino acids, minerals, vitamins, and trace elements
is an essential part of dietary management.
Pregnant women with PKU need appropriate
management to avoid raised levels of Phe with
teratogenic properties, leading to a host of birth
defects, especially microcephaly and congenital
heart disease (so-called maternal PKU syndrome)
(2, 3). Therefore, having a pregnant patient with
PKU is an important public health problem with
direct impacts on the offspring’s health and quality
of life (4). With that in mind, PKU women intending
to get pregnant are advised to use a restricted
low-Phe diet that starts at least 4 wk before con-
ception to prevent teratogenic effects of increased
Phe. However, the Phe intake should ensure the
necessary amount of the amino acid needed to
support the protein turnover for current body mass
of mother and fetus/es. During pregnancy, the Phe
tolerance may improve to some extent because
of the increased fetal activity of PAH. It should be
noted that there are limited pieces of evidence for
the practical management of pregnant PKU patient
(3, 5, 6). For example, the prediction of pheny-
lalanine tolerance changes during the course of
pregnancy is not clear.
The purpose of this case report is to describe
phenylketonuric woman with a very low increase
of Phe tolerance during pregnancies.
2. Case Presentation
A Caucasian patient of Polish origin was diag-
nosed with classical PKU at one month of age and
remained on phenylalanine-restricted diet until the
age of 17 years (IQ 105), however, her metabolic
control during adolescence was not fully satis-
factory. She became a food technologist. The
patient has had two pregnancies and did not
follow phenylalanine-restricted diet prior to the
conception in both and the cases; her whole
blood phenylalanine concentrations on normal diet
were above 1,200 µmol/L. She returned to dietary
phenylalanine restriction when she was almost
five wk pregnant and worked with a metabolic
dietitian ( J.Ż.) to stabilize blood Phe levels. Dietary
treatment included supplements and nutritional
mixtures specifically devised for pregnant PKU
patients (Table I), which were taken in 3-5 doses
per day. Whole blood Phe concentration has been
measured using the tandem mass spectrometer
technique (Ms/Ms) at least twice a week and a tar-
get range of phenylalanine of 120-360 µmol/L was
applied. If the blood Phe concentration remained
above acceptable range, Phe intake was slowly
decreased. The Phe intake was increased with-
out delay if the blood Phe concentration was ≤
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120 µml/L (3). The Phe tolerance was empirically
determined based on the analysis of fluctuations
of the patient’s blood Phe concentration in relation
to dietary Phe intake. Apart from the metabolic
physicians and dietary care, the pregnancies were
managed in the normal way by the obstetricians.
It should be noted that the patient’s prepreg-
nancy BMI was high (Table I). Moreover, her
mean total weight gain for pregnancies was 14.5
kg.
There were no obstetric complications through-
out the pregnancies and the babies were born
by normal delivery, see Table II for birth mea-
surements. None of the infants had PKU or any
degree of persistent hyperphenylalaninemia. The
neurodevelopment of offspring was normal over a
follow-up periods of at least three years.
During the courses of the first and second
pregnancies, the Phe tolerance increased 3.9-
and 2.3-times, respectively (Table III). Table I and
Figures 1 and 2 show what might not be consid-
ered as “satisfactory” metabolic control throughout
pregnancies since a huge number of assessments
of phenylalanine concentration was above the
target range. Tables IV and V present a puzzling
picture of the lack of association between maternal
weight gain, as well as fetal weight gain, and the
phenylalanine tolerance changes.
Table I. Clinical data on singleton pregnancies of a PKU patient resulting in live births
PKU patient (p.R408W /p.R408W)
Pregnancy 1 Pregnancy 2
Patient’s age at conception [yrs] 28 32
In vitro fertilization [Y/N] N N
Smoking during pregnancy [Y/N] N N
Pre-pregnancy weight [kg] 88 90
Pre-pregnancy BMI [kg/m2] 33.8 34.6
Pregnancy weight gain [kg] 16 13
BMI before delivery [kg/m2] 40 39.6
Weight gain in the first trimester [kg] 6.0 1.0
BMI in the first trimester [kg/m2] 36.1 35.0
Newborn weight as a proportion of maternal weight gain [%] 20 30
Preconceptional Phe level [µmol/L] 1272 (21.2 mg%) 1495 (24.9 mg%)
Gestational age when diet initiated [weeks] 6 5
Dietary formula* XP Maximum PKU express 20
% of Phe assessments > 360 µmol/L (6mg%) during the whole pregnancy 40 58
% of Phe assessments < 120 µmol/L (2mg%) during the whole pregnancy 2 0
14 Hbd 95.5 90
28 Hbd 119.5 95
34 Hbd 130 95
Daily protein intake from dietary formula [mg,g]*
37 Hbd 130 95
14 Hbd 1868-2268 1712-2099
28 Hbd 2483-2820 1850-2022
34 Hbd 2300-2500 1915-2203
Daily energy intake [kcal]
37 Hbd 2500-2700 2102-2368
PKU: Phenylketonuria Y/N: Yes/No BMI: Body mass index
Phe: Phenylalanine *to achieve optimal Phe control, natural sources of dietary proteins were greatly restricted
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1 37 M 3030 (> 50) 54 (> 97) 34 (> 50) 10 N 109 (1.8 mg%) N
2 39 M 4040 (> 90) 55 (> 97) 35 (> 50) 10 N 90 (1.5 mg%) N
PKU: Phenylketonuria Phe: Phenylalanine M/F: Male/female
*Whole blood phenylalanine concentration at newborn screening




Trimester 1 Trimester 2 Trimester 3 During the whole pregnancy
mg % mg % mg % mg %
1 165 (120→285) 137 178 (204→382) 87 169 (298→467) 56 347 (120→467) 289
2 69 (178→247) 39 167 (181→348) 92 168 (237→-405) 70 227 (178→405) 128
∗Based on average diet reconstructions
Table IV. Estimated phenylalanine tolerance and its ratio to the weight of the pregnant woman in the first and second pregnancies













7 964 157 1.69 504 190 2.03
14 424 293.5 3.12 646 204 2.25
28 302 318.5 3.19 391 305 3.11
37 261 439.5 4.23 331 314 3.02
39 368 350.5 3.40
Phe: Phenylalanine
Data are presented as: *average of at least two assessments; **average of minimum two diet reconstructions; ***ratio of tolerated
amount of Phe to the weight of the pregnant woman
Table V. Estimated phenylalanine tolerance and its ratio to fetal weight in the first and second pregnancies


















22 278 309 (297-320) 617 (597-640) 767 320 (281-360) 641 (562-720)
25 337 310 (263-357) 413 (351-476) 320 263 (237-289) 351 (316-385)
29 360 338 (309-367 282 (257-306) 390 343 (308-379) 286 (257-316)
30 379 333 (312-354) 238 (223-253) 354 338 (323-354) 242 (231-253)
31 453 374 (327-422) 234 (204-264) 462 333 (300-366) 208 (187-229)
32 319 345 (324-367) 192 (180-204) 333 364 (300-402) 202 (167-223)
33 301 383 (350-417) 192 (175-208) 338 355 (306-405) 178 (153-202)
34 351 423 (397-450) 188 (176-200) 398 334 (301-367) 148 (134-163)
35 257 387 (343-423) 154 (137-169) 424 330 (275-386) 132 (110-154)
36 315 398 (359-438) 148 (133-162) 398 342 (318-367) 127 (118-136)
37 261 439 (412-468) 149 (140-159) 332 354 (310-399) 120 (105-135)
38 324 336 (293-380) 107 (93-121)
39 368 350 (316-385) 105 (94-115)
Phe: Phenylalanine
Data are presented as: ∗average of minimum two assessments; ∗∗average of at least two diet reconstructions; ∗∗∗ratio of the
tolerated amount of Phe to the estimated weight of fetus
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Figure 1. Phenylalanine tolerance changes during the course of the first pregnancy.
Figure 2. Phenylalanine tolerance changes during the course of the second pregnancy.
Ethical consideration
The patient had given a written consent before
participating in the program of care for pregnant
PKUpatients developed by the Polish PKUConsen-
sus.
3. Discussion
Poor reproductive outcome is observed in PKU
women when dietary treatment is started late or
when blood Phe levels remain elevated. Hyper-
phenylalaninemia in women may affect amino
acid composition of uterine fluid (7). Maillot and
colleagues (5) demonstrated that the proportion
of time when the Phe concentrations in blood
are within the target range is greater in pregnant
PKU patients who started diet preconceptionally
than postconceptionally. Ideally, all PKU patients
wishing to become pregnant should do so in a
planned way. Unfortunately, both pregnancies in
our patient were unplanned. In Poland, in the
general population, a high number of conceptions
is unplanned (8, 9).
It has been demonstrated that after unsatisfied
pregnancy dietary treatment, infants have com-
monly smaller anthropometric measurements at
birth as well as impaired subsequent cognitive
development (2, 3, 5). In our case, the high number
of Phe assessments above 360 µmol/L was mostly
not caused by a lack of patient’s compliance andwe
observed normal neurodevelopment of patient’s
offspring. The Phe blood levels exceeded the
desirable upper limit in spite of a low Phe intake
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similar to the case of PKUmotherwith PKU-affected
fetus described by Kohlschütter and colleagues
(10).
We suspect that the patient’s low Phe tolerance
might be related to her sever PKU phenotype (11)
and the high prepregnancy BMI, as well as the
high BMI during the course of pregnancies. Early
body fat percentage strongly influence maternal
and fetal health (12). In the study by MacLeod and
colleagues (13), efforts to increase and maintain
lean weight seem to increase the Phe tolerance in
adult (non-pregnant) PKU patients. However, to our
knowledge, there have been no studies indicating
an effect of high preconceptional BMI and high BMI
during the course of pregnancy on the limitation of
Phe tolerance increase.
In the present case, good metabolic control was
not achieved even in late pregnancy, time when
increased phenylalanine requirement is expected
due to the fetal growth and its phenylalanine
hydroxylase activity in developing liver tissue (3,
6, 10, 14, 15). There was no impacting increase of
Phe tolerance expressed as mg/kg of pregnant
woman’s bodyweight (b.w.) in both the pregnancies
of our patient. In 1988, Hyánek and colleagues
(15) reported mean increase of Phe tolerance 3
mg/kg b.w. (26%) during the last three months
of pregnancy in a group of five women with
PKU (six pregnancies), who returned to a low
phenylalanine diet from the 5th or 6th month of
pregnancy. The Phe tolerances in the first, second,
and third trimesters of three PKU women (diet
before conception, six and eight wk gestation) from
the New England Maternal PKU Project were 450
mg (10 mg/kg b.w.), 720 mg (14 mg/kg b.w.), 1,300
mg (24mg/kg b.w.); 800mg (9mg/kg b.w.), 1,000mg
(14 mg/kg b.w.) 1,400 mg (14 mg/kg b.w.), and 675
mg (11 mg/kg b.w.), 1,300 mg (19 mg/kg b.w.), 1,500
mg (19 mg/kg b.w.), respectively (16). In one case,
where the dietary treatment started 10 wk before
conception, Thompson and colleagues (17) showed
an increase of Phe tolerance from 6 mg/kg b.w.
up to 30 mg/kg b.w. In our previous study, in two
singleton pregnancies of PKU women (PKU geno-
types: p.Q383X/p.R408W and p.R281L/p.R408W)
on diet initiated preconceptionally, the mean Phe
tolerance increased 12.1 mg/kg (172%) from 14
gestation wk to the pre-delivery week (18). Inter-
estingly, the American College of Medical Genetics
Guidelines on PKU (ACMGPractice Guidelines) rec-
ommended relatively high Phe intake for pregnant
phenylketonurics: 265-770 mg in trimester 1, 400-
1650 mg in trimester 2, and 700-2275 in trimester
3 (2), although based on the study of 23 pregnant
patients with good metabolic control, Acosta et al.
(19) provided data on the mean Phe tolerance in
trimesters 1, 2, and 3 of 609 ± 220mg, 824 ±
411mg, and 1248 ± 513mg, respectively. The PKU
patient (p.R408W/p.R261Q) reported by Duran and
colleagues (20), who began the Phe-restricted diet
at 13 wk of gestation had Phe tolerance of 300 mg
in the second trimester. In two PKU patients (PKU
genotypes: p.194del/p.P281L and p.165T/p.R408W)
described by Kohlschütter and colleagues (10) in
trimester 3, the Phe tolerance increased 900 mg
(100%) and 500 mg (50%), respectively. Interest-
ingly, in a pregnancy of the patient with the
genotype p.R408W/p.R261Q with a fetus homozy-
gous for PKU (genotype: p.R408W/p.R408W), the
Phe tolerance increase was approximately 200
mg in trimester 3, and during the course of
whole pregnancy, the Phe intake could not be
increased above 400-500 mg/day without risking
high Phe blood concentrations (10), which was
majorly below the lowest recommended value
of Phe intake for trimester 3 as per the ACMG
Practice Guidelines (2). In the European guidelines
on PKU (3), there is a suggestion based on the
Kohlschütter and colleagues study (10) that” a low
Phe tolerance in the third trimester of (treated)
pregnancy may indicate foetal PKU.” Levy and
colleagues (21) compared sibs with or without PKU
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from untreated pregnancies in phenylketonuric
mother and observed no effect of the fetal genetic
PKU status on maternal metabolic control as well
as offspring outcomes. We would like to stress that
described PKU woman gave birth to two healthy
children and the Phe intake could not be increased
above 470 mg/day in both the pregnancies; the
increase in the Phe tolerance in the third trimester
was below 200 mg. In the patient presented by us,
the late third trimester Phe tolerance in the second
pregnancy was 15% lower compared to the first
pregnancy. It is known that the Phe tolerance may
vary highly even between pregnancies in the same
patient (3). Hyánek and colleagues (15) reported the
Phe tolerance in two pregnancies of a PKU patient
before conception and during the 5th, 6th, 8th, and
9th month of pregnancy: 10.0, 11.0, 13.0, 15.0, 15.5
mg/kg b.w. and 6.8, 7.8, 9.0, 10.0, 11.0 mg/kg b.w.,
respectively.
4. Conclusion
In conclusion, both the pregnancies of the
presented PKU patient were difficult to manage
because the expected increase of Phe tolerance
did not take place. This case report does not
confirm the observation that a lack of impacting
Phe tolerance increase in pregnancy is a marker of
fetal PKU affection.
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